Engineering Tripterygium wilfordii-derived exosome-like nanoparticles for targeted therapy in rheumatoid arthritis

Abstract

Aim: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by excessive activation of pro-inflammatory macrophages and elevated levels of reactive oxygen species (ROS), resulting in synovial hyperplasia, cartilage destruction, and joint dysfunction. This study aimed to develop an engineered Tripterygium wilfordii-derived exosome-like nanoparticle system (TWELP@GlcN-HA) that integrates antioxidant, anti-inflammatory, immunomodulatory, and joint-targeting activities for synergistic RA therapy.

Methods:Tripterygium wilfordii-derived exosome-like nanoparticles (TWELP) were isolated from fresh Tripterygium wilfordii and sequentially surface-modified with glucosamine (GlcN) for cartilage protection and hyaluronic acid (HA) for targeted uptake by inflammatory cells. Their physicochemical properties, including morphology, particle size, structural integrity, and surface potential, were systematically characterized. In vitro assays were performed to evaluate ROS scavenging, inhibition of pro-inflammatory cytokines [tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)], and macrophage polarization. Biodistribution and therapeutic efficacy were evaluated in a collagen-induced arthritis (CIA) mouse model by assessing synovial inflammation, cartilage damage, joint morphology, and joint function.

Results: TWELP@GlcN-HA exhibited a uniform spherical morphology, stable surface potential, and preserved structural integrity. In vitro, it efficiently scavenged ROS, suppressed TNF-α and IL-6 secretion, and promoted macrophage polarization from M1 to M2, thereby restoring immune homeostasis. In vivo, HA-mediated targeting promoted nanoparticle accumulation in inflamed joints. TWELP@GlcN-HA significantly alleviated synovial inflammation and cartilage destruction, improved joint morphology and function, and exhibited excellent biosafety with no systemic toxicity.

Conclusion: TWELP@GlcN-HA provides a multifunctional combinatorial strategy for RA treatment by synergistically regulating ROS, reprogramming pro-inflammatory macrophages, protecting cartilage, and achieving targeted joint delivery. Its enhanced therapeutic efficacy and favorable safety profile make it a promising candidate for future clinical translation in RA management.

Keywords

Rheumatoid arthritis / exosome-like nanoparticles / Tripterygium wilfordii

References

[1] Smolen JS,Aletaha D,McInnes IB. Rheumatoid arthritis Lancet 2016 388 2023 38

[2] GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021 Lancet Rheumatol 2023 5 e594 610 PMC10546867

[3] Safiri S,Kolahi AA,Hoy D.et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017 Ann Rheum Dis 2019 78 1463 71

[4] Jin J,Cai X,Rao P,Xu J,Li J. Microbiota and immune dynamics in rheumatoid arthritis: Mechanisms and therapeutic potential Best Pract Res Clin Rheumatol 2025 39 102035

[5] Catrina AI,Deane KD,Scher JU. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis Rheumatology 2016 55 391 402 PMC4746430

[6] Boutet MA,Courties G,Nerviani A.et al. Novel insights into macrophage diversity in rheumatoid arthritis synovium Autoimmun Rev 2021 20 102758

[7] Konzett V,Aletaha D. Management strategies in rheumatoid arthritis Nat Rev Rheumatol 2024 20 760 9

[8] Nygaard G,Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes Nat Rev Rheumatol 2020 16 316 33 PMC7987137

[9] Guo D,Liu H,Zhao S.et al. Synergistic rheumatoid arthritis therapy by interrupting the detrimental feedback loop to orchestrate hypoxia M1 macrophage polarization using an enzyme-catalyzed nanoplatform Bioact Mater 2024 41 221 38 PMC11324459

[10] Hanlon MM,Smith CM,Canavan M.et al. Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset Sci Adv 2024 10 eadj1252 PMC11423874

[11] Wang Y,Shi P,Chen Q.et al. Mitochondrial ROS promote macrophage pyroptosis by inducing GSDMD oxidation J Mol Cell Biol 2019 11 1069 82 PMC6934151

[12] Ding Z,Liu S,Wang X.et al. LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis Cardiovasc Res 2014 103 619 28 PMC4200051

[13] Komatsu N,Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions Nat Rev Rheumatol 2022 18 415 29

[14] Prasad P,Verma S,Surbhi,Ganguly NK,Chaturvedi V,Mittal SA. Rheumatoid arthritis: advances in treatment strategies Mol Cell Biochem 2023 478 69 88

[15] Jung SM,Han M,Kim EH,Jung I,Park YB. Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018 Arthritis Res Ther 2022 24 157 PMC9235163

[16] Biesemann N,Margerie D,Asbrand C.et al. Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis Sci Transl Med 2023 15 eabq4419

[17] Lauper K,Kearsley-Fleet L,Galloway JB,Watson KD,Hyrich KL,Lunt M. BSRBR-RA Contributors Group Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter? Rheumatology 2024;63:1957-64 PMC11215981

[18] Zhang R,Lin X,Lin R.et al. Effectively alleviate rheumatoid arthritis via maintaining redox balance, inducing macrophage repolarization and restoring homeostasis of fibroblast-like synoviocytes by metformin-derived carbon dots J Nanobiotechnology 2025 23 58 PMC11776225

[19] Zhang X,Fu X,Chen W.et al. Amelioration of the rheumatoid arthritis microenvironment using celastrol-loaded silver-modified ceria nanoparticles for enhanced treatment J Nanobiotechnology 2025 23 372 PMC12100825

[20] Zhang Y,Mao X,Li W.et al. Tripterygium wilfordii: an inspiring resource for rheumatoid arthritis treatment Med Res Rev 2021 41 1337 74

[21] Tong L,Zhao Q,Datan E.et al. Triptolide: reflections on two decades of research and prospects for the future Nat Prod Rep 2021 38 843 60

[22] Sarasati A,Syahruddin MH,Nuryanti A.et al. Plant-derived exosome-like nanoparticles for biomedical applications and regenerative therapy Biomedicines 2023 11 1053 PMC10136114

[23] Bai C,Liu J,Zhang X.et al. Research status and challenges of plant-derived exosome-like nanoparticles Biomed Pharmacother 2024 174 116543

[24] Yi Q,Xu Z,Thakur A.et al. Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment Pharmacol Res 2023 190 106733

[25] Lin Y,Yi O,Hu M.et al. Multifunctional nanoparticles of sinomenine hydrochloride for treat-to-target therapy of rheumatoid arthritis via modulation of proinflammatory cytokines J Control Release 2022 348 42 56

[26] Zheng BY,Wang XJ,Wen HS.et al. Exosomes-mediated molecular mechanisms underlying the transformation of ovarian tissue into a functional placental analogue in black rockfish (Sebastes schlegelii) Zool Res 2026 47 1661 77

[27] Li P,Yang X,Yang Y.et al. Synergistic effect of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice J Control Release 2020 319 87 103

[28] Brand DD,Latham KA,Rosloniec EF. Collagen-induced arthritis Nat Protoc 2007 2 1269 75

[29] Yang Y,Guo L,Wang Z.et al. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization Biomaterials 2021 264 120390

[30] Ruffell B,Poon GF,Lee SS.et al. Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in inflammatory and interleukin 4-activated macrophages J Biol Chem 2011 286 19179 90 PMC3103297

[31] Rios de la Rosa JM,Tirella A,Gennari A,Stratford IJ,Tirelli N. The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages Adv Healthc Mater 2017 6 1601012

[32] Walvekar P,Lulinski P,Kumar P,Aminabhavi TM,Choonara YE. A review of hyaluronic acid-based therapeutics for the treatment and management of arthritis Int J Biol Macromol 2024 264 130645

[33] Yang X,Li J,Xu C,Zhang G,Che X,Yang J. Potential mechanisms of rheumatoid arthritis therapy: Focus on macrophage polarization Int Immunopharmacol 2024 142 113058

[34] Fang WY,Tseng YT,Lee TY.et al. Triptolide prevents LPS-induced skeletal muscle atrophy via inhibiting NF-κB/TNF-α and regulating protein synthesis/degradation pathway Br J Pharmacol 2021 178 2998 3016

[35] Lv C,Cheng T,Zhang B,Sun K,Lu K. Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway Ren Fail 2023 45 2165103 PMC10035962

[36] Udagawa N,Koide M,Nakamura M.et al. Osteoclast differentiation by RANKL and OPG signaling pathways J Bone Miner Metab 2021 39 19 26

[37] Wu YZ,Chen WY,Zeng Y.et al. Inflammation-responsive mesoporous Silica nanoparticles with synergistic anti-inflammatory and joint protection effects for rheumatoid arthritis treatment Pharm Res 2024 41 1493 505

[38] Priya S,Verma V,Roy A,Singhvi G. Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment J Nanobiotechnology 2025 23 725 PMC12632076

[39] Qadri MM. Targeting CD44 receptor pathways in degenerative joint diseases: involvement of proteoglycan-4 (PRG4) Pharmaceuticals 2023 16 1425 PMC10609794

[40] Cui D,Xu D,Yue S.et al. Recent advances in the pharmacological applications and liver toxicity of triptolide Chem Biol Interact 2023 382 110651

[41] Zhang C,Weng Y,Wang H.et al. A synergistic effect of triptolide and curcumin on rheumatoid arthritis by improving cell proliferation and inducing cell apoptosis via inhibition of the IL-17/NF-κB signaling pathway Int Immunopharmacol 2024 142 112953

[42] Gouze JN,Gouze E,Popp MP.et al. Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta Arthritis Res Ther 2006 8 R173 PMC1794517

[43] Stoppoloni D,Politi L,Leopizzi M.et al. Effect of glucosamine and its peptidyl-derivative on the production of extracellular matrix components by human primary chondrocytes Osteoarthritis Cartilage 2015 23 103 13

[44] Wang P,Zhang Y,Lei H.et al. Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis Carbohydr Polym 2023 316 121018

[45] Naor D,Nedvetzki S. CD44 in rheumatoid arthritis Arthritis Res Ther 2003 5 105 15 PMC165042

[46] Jin K,Luo Z,Zhang B,Pang Z. Biomimetic nanoparticles for inflammation targeting Acta Pharm Sin B 2018 8 23 33 PMC5985691

[47] Rahman M,Beg S,Anwar F.et al. Liposome-based nanomedicine therapeutics for rheumatoid arthritis Crit Rev Ther Drug Carrier Syst 2017 34 283 316

[48] Han Z,Gao X,Wang Y.et al. Ultrasmall iron-quercetin metal natural product nanocomplex with antioxidant and macrophage regulation in rheumatoid arthritis Acta Pharm Sin B 2023 13 1726 39 PMC10150182

[49] Buttari B,Recalchi S,Riitano G.et al. Extracellular microvesicles from patients with Rheumatoid arthritis promote dendritic cell activation in vitro Front Immunol 2025 16 1532114 PMC11920144

[50] Riitano G,Recalchi S,Capozzi A.et al. The role of autophagy as a trigger of post-translational modifications of proteins and extracellular vesicles in the pathogenesis of rheumatoid arthritis Int J Mol Sci 2023 24 12764 PMC10454292

[51] Longo A,Manganelli V,Misasi R.et al. Extracellular vesicles in the crosstalk of autophagy and apoptosis: a role for lipid rafts Cells 2025 14 749 PMC12109985